Sugi Predict

Sugi Predict / Compounds / SCHEMBL1668291

SCHEMBL1668291

SCHEMBL1668291

O=c1[nH]c2ccc(O)cc2c(=O)o1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 1/20 0.56
▸ CFD P00746 1/20 0.56
▸ CDK5 Q00535 4/20 0.54
▸ CDK5R1 Q15078 4/20 0.54
▸ DYRK1A Q13627 3/20 0.54
▸ TOP1 P11387 1/20 0.53
▸ GSK3A P49840 1/20 0.53
▸ GSK3B P49841 1/20 0.53
▸ MAOA P21397 9/20 0.52
▸ MAOB P27338 9/20 0.52
▸ ACHE P22303 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ CASP6 P55212 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ PDE2A O00408 1/20 0.49
▸ ROCK2 O75116 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3597944 0.79 KDM4E (0.54) F2CFDMAOAMAOBACHE
SCHEMBL62706 0.78 LMNA (0.58) F2CFDMAOAMAOBACHE
SCHEMBL3132671 0.78 MAOA (0.57) F2CFDGSK3AGSK3BMAOA
SCHEMBL29891935 0.78 MAOA (0.61) F2CFDCDK5CDK5R1MAOA
SCHEMBL30908765 0.78 LMNA (0.58) F2CFDMAOAMAOBACHE
SCHEMBL14448380 0.78 F2 (0.56) F2CFDMAOAMAOBACHE
SCHEMBL694149 0.78 MAOA (0.61) F2CFDCDK5CDK5R1MAOA
SCHEMBL1202291 0.78 NOS1 (0.62) F2CFDMAOAMAOBACHE
SCHEMBL1147630 0.78 F2 (0.56) F2CFDMAOAMAOBACHE
SCHEMBL31460362 0.78 MAOA (0.57) F2CFDGSK3AGSK3BMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4728673-A BLOWING AGENT OF ISATOIC ANHYDRIDE DERIVATIVE IN PRESCENT OF NEUTRAL SALT BAYER AKTIENGESELLSCHAFT (DE) 1988-03-01 — — US claimed
US-20250215008-A1 PREPARATION AND USE OF QUINAZOLINONE DERIVATIVE AS KINASE INHIBITOR Haisco Pharmaceutical Group Co., Ltd. (CN) 2025-07-03 — — US disclosed
CN-119585269-A Preparation and use of quinazolinone derivatives as kinase inhibitors 海思科医药集团股份有限公司 2025-03-07 — — CN disclosed
US-20230227416-A1 SUBSTITUTED BENZOTRIAZINONE METABOLITES OF A GPR139 AGONIST TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-07-20 — — US disclosed
US-20230227416-A1 SUBSTITUTED BENZOTRIAZINONE METABOLITES OF A GPR139 AGONIST TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-07-20 — — US disclosed
US-20230117920-A1 Library Construction Method, Cyclic Peptide, FXIIa Binder and IFNGR1 Binder THE UNIVERSITY OF TOKYO (JP) 2023-04-20 — — US disclosed
EP-4146635-A1 SUBSTITUTED BENZOTRIAZINONE METABOLITES OF A GPR139 AGONIST Takeda Pharmaceutical Company Limited (JP) 2023-03-15 — — EP disclosed
EP-4101929-A1 LIBRARY CONSTRUCTION METHOD, CYCLIC PEPTIDE, FXIIA BINDER AND IFNGR1 BINDER The University of Tokyo (JP) 2022-12-14 — — EP disclosed
WO-2021224680-A1 SUBSTITUTED BENZOTRIAZINONE METABOLITES OF A GPR139 AGONIST TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-11-11 — — WO disclosed
WO-2021132661-A1 LIBRARY CONSTRUCTION METHOD, CYCLIC PEPTIDE, FXIIa BINDER AND IFNGR1 BINDER 国立大学法人東京大学 2021-07-01 — — WO disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 — — US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 — — US disclosed
US-20020103371-A1 Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives HOFFMANN-LA ROCHE INC. 2002-08-01 — — US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 — — US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 — — EP disclosed
US-5872115-A COMPOUNDS FOR TREATMENT OF HYPERCHOLESTEROLEMIA, ISCHEMIC HEART DISEASE, CEREBROVASCULAR DISEASE OR ATHEROSCLEROSIS GRELAN PHARMACEUTICAL CO. LTD. (JP) 1999-02-16 — — US disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 — — WO disclosed
EP-0234219-B1 PROCESS FOR FOANING ESTER AND/OR CARBONATE GROUPS CONTAINING THERMOPLASTIC RESINS BAYER AG (DE) 1990-04-18 — — EP disclosed
US-4728673-A BLOWING AGENT OF ISATOIC ANHYDRIDE DERIVATIVE IN PRESCENT OF NEUTRAL SALT BAYER AKTIENGESELLSCHAFT (DE) 1988-03-01 — — US disclosed
EP-0234219-A2 Process for foaning ester and/or carbonate groups containing thermoplastic resins BAYER AG (DE) 1987-09-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103371-A1 Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives GABRA5, GABRA1, GABRA4 F2 3166/4885CFD 4607/4885CDK5 1946/4885
US-20230227416-A1 SUBSTITUTED BENZOTRIAZINONE METABOLITES OF A GPR139 AGONIST GPR139, GPR84, GPR3 F2 4369/4885CFD 4811/4885CDK5 3692/4885
US-20230117920-A1 Library Construction Method, Cyclic Peptide, FXIIa Binder and IFNGR1 Binder IFNAR1, IFNG, F13A1 F2 25/4885CFD 259/4885CDK5 3105/4885
US-20250215008-A1 PREPARATION AND USE OF QUINAZOLINONE DERIVATIVE AS KINASE INHIBITOR BRAF, RAF1, NRAS F2 4189/4885CFD 1937/4885CDK5 250/4885
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 F2 16/4885CFD 134/4885CDK5 3716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.